5-amino-6-chloro-2-methyl-N-{[1-(1,3,3-trimethyl-2-oxobutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide | 676351-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 5-amino-6-chloro-2-methyl-N-{[1-(1,3,3-trimethyl-2-oxobutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide
• 英文别名: 5-amino-6-chloro-N-[[1-(4,4-dimethyl-3-oxopentan-2-yl)piperidin-4-yl]methyl]-2-methylimidazo[1,2-a]pyridine-8-carboxamide
• CAS: 676351-73-8
• 化学式: C₂₂H₃₂ClN₅O₂
• 分子量: 433.981
• InChiKey: KMEQPWYPKMOFLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-amino-6-chloro-2-methyl-N-(piperidine-4-ylmethyl)imidazo[1,2-a]pyridin-8-carboxamide dihydrochloride 、 2-溴-4,4-二甲基-3-戊酮 在 potassium carbonate 、 potassium iodide 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 16.0h， 以15%的产率得到5-amino-6-chloro-2-methyl-N-{[1-(1,3,3-trimethyl-2-oxobutyl)piperidin-4-yl]methyl}imidazo[1,2-a]pyridine-8-carboxamide
  参考文献：
  名称：

  [EN] N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS
  [FR] COMPOSES DE PIPERIDINYL-IMIDAZOPYRIDINE N-SUBSTITUES UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4

  摘要：

  这项发明提供了一个化合物的结构式(I)：其中R1代表氢原子或卤原子；R2代表氢原子，等等；R3代表具有1至10个碳原子的烷基基团；R3中的烷基基团被来自α取代基组的至少一个取代基所取代；所述α取代基选自芳基、羟基、酮基等组成的组；所述芳基含有6至10个碳原子；所述芳基未取代或被具有1至6个碳原子的至少一个烷基基团所取代；所述杂环基团和杂环基团中的杂环基在杂环羰基中是含有1至4个来自氮原子等组成的杂原子的5至10元环基团；或者是该化合物的药学上可接受的酰胺，或者是该化合物的药学上可接受的酯，以及其药学上可接受的盐。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。

  公开号：

  WO2004026868A1

文献信息

• N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
  申请人：Pfizer Inc

  公开号：US20040127514A1

  公开（公告）日：2004-07-01

  This invention provides a compound of the formula (I): 1 or a pharmaceutically acceptable salt, amide or ester thereof, wherein R 1 represents a hydrogen atom or a halogen atom; R 2 represents a hydrogen atom, etc.; R 3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group of R 3 is substituted by at least one substituent selected from the group consisting of substituents &agr;; said substituents &agr; is aryl, hydroxy, oxo, etc.; said aryl having 6 to 10 carbon atoms; said aryl is unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic and the heterocyclic moiety of said heterocycliccarbonyl, both of substituents &agr;, are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms These compounds have 5-HT 4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了化合物(I)的化合物：1或其药学上可接受的盐，酰胺或酯，其中R1代表氢原子或卤素原子; R2代表氢原子等; R3代表具有1到10个碳原子的烷基基团; R3的烷基基团被选自取代基&agr;的至少一种取代; 该取代基&agr;是芳基，羟基，氧代或其他; 该芳基具有6到10个碳原子; 该芳基未取代或被至少一个具有1到6个碳原子的烷基基团取代; 该杂环和该杂环羰基的杂环基团，取代基&agr;均为5至10个成员的环状基团，包含1至4个选自氮原子，氧原子和硫原子的杂原子。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征或类似疾病的治疗有用。本发明还提供了包含上述化合物的制药组合物。
• [EN] N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS<br/>[FR] COMPOSES DE PIPERIDINYL-IMIDAZOPYRIDINE N-SUBSTITUES UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4
  申请人：PFIZER PHARMA

  公开号：WO2004026868A1

  公开（公告）日：2004-04-01

  This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α are selected from the group consisting of aryl groups, hydroxy groups, oxo groups, etc.; said aryl groups have 6 to 10 carbon atoms; said aryl groups are unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic groups and heterocyclic moiety in heterocycliccarbonyl groups are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, etc.; or a pharmaceutically acceptable amide of such compound, or a pharmaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物的结构式(I)：其中R1代表氢原子或卤原子；R2代表氢原子，等等；R3代表具有1至10个碳原子的烷基基团；R3中的烷基基团被来自α取代基组的至少一个取代基所取代；所述α取代基选自芳基、羟基、酮基等组成的组；所述芳基含有6至10个碳原子；所述芳基未取代或被具有1至6个碳原子的至少一个烷基基团所取代；所述杂环基团和杂环基团中的杂环基在杂环羰基中是含有1至4个来自氮原子等组成的杂原子的5至10元环基团；或者是该化合物的药学上可接受的酰胺，或者是该化合物的药学上可接受的酯，以及其药学上可接受的盐。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。